L'équipe du département de pharmacologie






Université Bordeaux 2 CHU de Bordeaux INSERM
Département Hospitalo-Universitaire de Pharmacologie de Bordeaux
  • Home
  • Publications in 2018


Publications' last update : 2018-03-06

  1. Adverse drug reactions of analgesic medicines: analysis of the Romanian pharmacovigilance database
    Fundam Clin Pharmacol. 2018 (ahead of print)
    Cazacu I, Stroe R, Dondera R, Mogosan C, Haramburu F, Fourrier-Réglat A, Loghin F.
     PubMed citation

  2. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions
    Br J Clin Pharmacol. 2018 (ahead of print)
    Deljehier T, Pariente A, Miremont-Salamé G, Haramburu F, Nguyen L, Rubin S, Rigothier C, Théophile H.
     PubMed citation

  3. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS
    J Pharm Biomed Anal. 2018 (150) 112-120
    Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M, Bouchet S.
     PubMed citation

  4. Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users
    Eur J Clin Pharmacol. 2018 (ahead of print)
    Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A.
     PubMed citation

  5. Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics
    Postgrad Med. 2018 (ahead of print)
    Moore N, Scheiman JM.
     PubMed citation

  6. Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis
    Vaccine. 2018 (ahead of print)
    Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, Bégaud B.
     PubMed citation

  7. Detection of drug safety signals from clinical trials data: Role of SUSARs
    Pharmacol Res. 2018 (ahead of print)
    Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, Toulza E, Becker M, Hamy L, Crepin S, Roussillon C, Gimbert A, Petitpain N, Salvo F.
     PubMed citation

  8. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort
    Clin Colorectal Cancer. 2018 (ahead of print)
    Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group.
     PubMed citation